The newly cleared device is designed to divert blood flow from aneurysms to promote healing and reduce the risk of rupture, the company said. The Bravo is Cerenovus’ first flow diverter device, the company added.
“Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms. I believe the design of the Bravo flow diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms,” Bravo flow diverter evaluator Dr. Patrick Brouwer of Karolinska University Hospital said in a prepared statement.
“The Bravo flow diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke. Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke,” Cerenovus worldwide prez Daniella Cramp said in a press release.
In May, Cerenovus said that it won FDA 510(k) clearance for the Embotrap II revascularization device.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.